HOSPITAL UNIVERSITARIO RUBER
Departamento
University of Leeds
Leeds, Reino UnidoPublicaciones en colaboración con investigadores/as de University of Leeds (7)
2024
-
The evolving value assessment of cancer therapies: Results from a modified Delphi study
Health Policy OPEN, Vol. 6
2022
-
Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases: Final Results From the Phase 3 ATTAIN Randomized Clinical Trial
JAMA Oncology, Vol. 8, Núm. 7, pp. 1047-1052
2015
-
"New" metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapy
Breast Cancer Research, Vol. 17, Núm. 1
-
Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): A randomised, open-label, multicentre, phase 3 trial
The Lancet Oncology, Vol. 16, Núm. 15, pp. 1556-1568
-
Recognizing the place of trials with treatment of physician's choice as the control Arm
Journal of Clinical Oncology
2014
-
Eribulin monotherapy in patients aged 70 years and older with metastatic breast cancer
Oncologist, Vol. 19, Núm. 4, pp. 318-327
2011
-
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): A phase 3 open-label randomised study
The Lancet, Vol. 377, Núm. 9769, pp. 914-923